Who makes Phosphate Buffer Saline (PBS),?

Phosphate Buffer Saline (PBS), is developed by Shire.

What development phase is Phosphate Buffer Saline (PBS), in?

Phosphate Buffer Saline (PBS), is in Phase 3.

Last reviewed 2026-04-23 · How we verify

Phosphate Buffer Saline (PBS),

Shire · Phase 3 active Small molecule

PBS is a buffered saline solution that maintains physiological pH and osmolarity, serving as a vehicle or diluent rather than an active pharmaceutical agent.

At a glance

Generic name	Phosphate Buffer Saline (PBS),
Sponsor	Shire
Modality	Small molecule
Phase	Phase 3

Mechanism of action

Phosphate Buffer Saline is a standard laboratory and clinical reagent composed of sodium chloride, sodium phosphate, and potassium phosphate that creates an isotonic, pH-neutral environment. It is not a drug with a therapeutic mechanism of action, but rather a formulation excipient or delivery vehicle commonly used in pharmaceutical manufacturing, cell culture, and clinical applications to maintain biological stability and compatibility.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Phosphate Buffer Saline (PBS), CI brief — competitive landscape report
Phosphate Buffer Saline (PBS), updates RSS · CI watch RSS
Shire portfolio CI